A new study has been published that suggests humans have a hard limit for living, and once that limit is reached, the body is no longer able to repair itself.
Biomarker Discovery Could Aid Development of Senolytic Drugs Against Age-Related Disorders
April 5, 2021
Share
Buck Institute researchers have discovered a novel biomarker, detectable in blood and urine, which could form the basis of a noninvasive test to measure and track the performance of senolytics, a class of drugs that selectively eliminate senescent cells. The oxylipin biomarker, 15-deoxy-delta-12, 14-prostaglandin J2 (dihomo-15d-PGJ2), is a signaling lipid metabolite oxylipin molecule that normally accumulates inside cells, but is released when senescent cells die, and can be detected in urine and blood. The results of the team’s newly reported studies in cultured cells and in mice could aid the development of senolytic drugs against a range of chronic age-related conditions, such as arthritis, lung disease, Alzheimer’s disease, and glaucoma. And with a growing list of such treatments in development, detecting the dihomo-15d-PGJ2 oxylipin via a companion diagnostic cou